iBio (IBIO) vs XBiotech (XBIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
iBio (IBIO) has outperformed XBiotech (XBIT) over the past year, losing 23.8% versus a loss of 24.1%. Over five years, XBIT leads with a -86.5% price change compared with -99.8% for IBIO. iBio is the larger company by market cap ($56.4 million vs $52.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBIO | XBIT |
|---|---|---|
| Share price | $0.8001 | $1.73 |
| Market cap | $56.37M | $52.74M |
| 1-day change | -0.11% | +2.98% |
| YTD return | -58.54% | -27.62% |
| 1-year return | -23.80% | -24.12% |
| 5-year return | -99.76% | -86.48% |
| Forward P/E | — | 13.31 |
| EPS (TTM) | $-0.27 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $100.00K | — |
| Revenue growth (YoY) | -75.00% | — |
| Net income (latest FY) | $-33.04M | $-45.54M |
| Operating margin | -35141.00% | — |
| Net margin | -33044.00% | — |
| 52-week high | $3.82 | $2.73 |
| 52-week low | $0.68 | $1.61 |
| Distance from 52-week high | -79.05% | -36.63% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +611.16% | — |
| Average volume | 678.91K | 64.77K |
| Shares outstanding | 70.46M | 30.49M |
| Employees | 23 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About iBio
IBIO stock →iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large target proteins Its product pipelines for cardiometabolic disease area include IBIO-601, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass; IBIO-600 Myostatin Antibody, monoclonal antibody blocking myostatin that is in phase 1; Amylin Antibody, a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor; CCR8, a Treg-targeting immunotherapy; and MUC16 antibodies.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About XBiotech
XBIT stock →XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
IBIO vs XBIT FAQ
Which is bigger, iBio or XBiotech?
iBio (IBIO) is larger, with a market capitalization of $56.37M compared with $52.74M for XBiotech (XBIT).
Which stock has performed better over the past year, IBIO or XBIT?
IBIO returned -23.80% over the past 12 months, compared with -24.12% for XBIT (price return, excluding dividends). Past performance does not predict future results.
Are iBio and XBiotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.